image: Cartoon depicting the overall pathway involved in MRGPRX2 mediated monocyte recruitment and differentiation. P17 activation of MRGPRX2, but not IgE receptor in mast cells resulting in cytokine releases (MCP-1, MIP1-α, GM-CSF and M-CSF) and subsequent monocyte recruitment and differentiation. view more
Credit: The University of Hong Kong
Ants are omnipresent, and we often get blisters after an ant bite. But do you know the molecular mechanism behind it? A research team led by Professor Billy K C CHOW from the Research Division for Molecular and Cell Biology, Faculty of Science, the University of Hong Kong (HKU), in collaboration with Dr Jerome LEPRINCE from The Institut national de la santé et de la recherche médicale (INSERM) and Professor Michel TREILHOU from the Institut National Universitaire Champollion in France, have identified and demonstrated a novel small peptide isolated from the ant venom can initiate an immune pathway via a pseudo-allergic receptor MRGPRX2. The study has recently been published in a top journal in Allergy - The Journal of Allergy and Clinical Immunology.
Allergy is a common undesirable immune response for most people, and are often caused by allergens such as food, pollen, drugs, mites, bites and stings from venomous insects etc. When an allergic reaction happens, mast cells that line the body surfaces alert the immune system by releasing cytokines. Thus, other immune cells are recruited to the infected area to clear the allergens.
There are two kinds of allergic reaction: allergic and pseudo allergic reactions. Allergic reactions are triggered when allergens bind to the high-affinity IgE receptor on mast cells, whereas the pseudo allergic reactions are majorly triggered when allergens bind to MRGPRX2 on mast cells. Therefore, different medical treatments are required to contain them.
Recently, the discovery of IgE and MRGPRX2 expressed receptors in mast cells has helped us to understand the root cause of most allergic and pseudo allergic reactions. However, functional characterisation of MRGPRX2 is very limited since it has not got much attention in the allergic field as a pseudo allergic receptor until recently, whereas the former is very well studied. The function of MRGPRX2, other than being a pseudo allergic receptor, is largely unknown and yet to be explored.
For instance, pseudo allergic reactions can be induced by various FDA approved drugs. So, understanding this pseudo allergic mechanisms will help in developing drugs without side effects. In addition, understanding of pseudo allergic reactions will also help in developing antagonists that would minimise clinically relevant MRGPRX2 mediated allergic reactions such as rosacea or red man syndrome.
Through concerted efforts, our research team identifies and demonstrates a naturally abundant venom peptide from ants that activates a previously unknown pseudo allergic pathway, which in turn, help to discover other function of MRGPRX2, sheding light on the non-pseudo allergic function of MRGPRX2.
Research background
Insect venoms are biochemical arsenals developed by animals to defend themselves. Interestingly, arthropods contain the maximum number of species capable of making venoms that can produce biological effects in our body. Particularly, ants are the most dominant and diversified species with more than 14,700 known species and the biggest biomass in most territorial ecosystems. Therefore, Insect venoms are very important resources for us containing a treasure of biologically active chemicals, peptides and proteins. For instance, Purotoxin-1 (PT1), Apamin and Bicarinalin are bioactive peptides isolated from various insect venoms that are known to play a role in inflammatory pain, antimicrobial effects and cytotoxic effects against cancer cells.
P17 is a short host defence peptide isolated from the venom of an ant Tetramorium bicarinatum. We have recently demonstrated its involvement in our body defence system via interacting with an unknown receptor to activate the immune system to kill the fungal infection in mice lungs. P17, therefore can be exploited as a therapeutic peptide for inflammatory disorders or cancer and pseudo allergic reactions. In this study, after screening almost the entire human G protein-coupled receptor repertoire, we have successfully identified a specific human receptor or Mas-related G protein-coupled receptor-X2 (MRGPRX2) that is responsible for interacting with P17 to carry out its activity.
Key findings
The research team has extensively worked on identifying a lock (GPCR) for a key (P17) by trying about 400 locks for a single key and eventually identified the GPCR for P17. In addition, we also demonstrated the molecular pathways of P17-MRGPRX2 mediated activation of mast cells, an immune cell that is responsible for the allergic reaction. Upon deorphanising of P17, we then used computational approaches to find the important amino acids (ridges in the key) that are important for the binding of the venom peptide with its receptor - like a key ridge in the key for a lock.
Our team then uncovered a novel pathway for this receptor. We showed P17 induces infiltration of monocytes at the injected site by activating MRGPRX2. The effect is quite similar to an ant bite in humans. Once the ant bites you, you will have blisters/swelling, which indicates the immune cell infiltration at the bite site to remove the ant venom. Usually, our body detects the external substances (arrows in the diagram) via receptors (targets) and act upon those external substances to clear them out. In this scenario, P17 is the arrow detected by MRGPRX2 of mast cells to recruit monocytes and differentiates them into macrophages to engulf and clear the pathogens. To the best of our knowledge, we demonstrated for the first time that MRGPRX2 mediated activation of mast cell could recruit human monocyte and differentiate them into macrophages. This study shows a novel immunomodulatory effect of MRGPRX2 and suggests that it is a vital receptor in innate immunity.
Societal impact of the findings
Firstly, a novel immunomodulatory pathway of MRGPRX2 has been demonstrated, which could enhance the overall understanding of the receptor function among the scientific community. Additionally, Macrophages are specialised cells involved in the detection, phagocytosis and destruction of bacteria and other harmful organisms. Thus, using this novel information, we can design new analogues that are agonists or antagonists of MRGPRX2 to modify our immune response to deal with host defence, allergic or other immune diseases.
"We demonstrated that peptides isolated from venoms can be used to modulate immune responses and these peptides are abundant in nature. One key message we should take from this finding is biodiversity is one of the greatest treasure we have and we just have to use them wisely," said Professor Chow. "Our findings are evident that novel scientific innovations come from observing the nature. Ant bite leads to immune cell infiltration, so we just isolated the peptide that recruits the immune cells that can be beneficial," said Dr Duraisamy. Besides, the HKU team's laboratory has established a platform for translating basic biology into novel drug discoveries as we already have filed a patent for the design and synthesis of a group of drugs with high efficacies to translate them into societal impact. Using this novel pathway we could eventually tweak it a bit to our benefit to kill off pathogens during infection.
Research Team
The research was conducted by the team led by Professor Billy KC CHOW from the Research Division for Molecular and Cell Biology. Dr Karthi DURAISAMY from Professor Chow's group is the first author of the paper, while Dr Jérôme LEPRINCE is the co-corresponding author of the paper. Professor Michel TREILOU, Dr Elsa BONNAFÉ, Dr Kailash SINGH, Mr Benjamin LEFRANC and Mr Mukesh KUMAR contributed to the research.
###
The research has been supported by various grants from the Research Grants Council of Hong Kong and European Regional Development Fund. This work was supported by HK government RGC Grant GRF 1711320 and 17111421, NSFC/RGC and HKU seed fund for basic research 201910159222 to BKCC. Institut National de la Santé et de la Recherche Médicale (Inserm), the Normandy University (Rouen), the Region Normandy, the European Union (PHEDERCPG and 3R projects) and Europe gets involved in Normandy with European Regional Development Fund (ERDF) to JL.
About Professor Chow
Professor Billy KC Chow focuses on novel therapeutic molecules for the treatment of major critical diseases that involves GPCRs. Using his years of experience in basic research, he has founded a start-up company PhrmaSec Ltd, which aims to translate basic research into major societal impact. His expertise lies in GPCRs in general with GPCR physiological functions, and target receptor identification and their molecular mechanisms of novel bioactive agents.
More information about Professor Chow and his research group: https://www.scifac.hku.hk/people/chow-billy-kwok-chong
About the research paper: https://doi.org/10.1016/j.jaci.2021.04.040
Images download and captions: https://www.scifac.hku.hk/press
For media enquiries, please contact Ms Casey To, External Relations Officer (tel: 3917 4948; email: caseyto@hku.hk / Ms Cindy Chan, Assistant Director of Communications of HKU Faculty of Science (tel: 3917 5286; email: cindycst@hku.hk).
Journal
Journal of Allergy and Clinical Immunology